Article
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2017
Verboom Michiel C, Kloth Jacqueline S L, Swen Jesse J, van der Straaten Tahar, Bovée Judith V M G, Sleijfer Stefan, Reyners Anna K L, Mathijssen Ron H J, Guchelaar Henk-Jan, Steeghs Neeltje, Gelderblom Hans
Abstract excerpt
BACKGROUND: Imatinib 400 mg per day is first-line therapy for patients with gastrointestinal stromal tumours (GISTs). Although clinical benefit is high, progression-free survival (PFS) is variable. This study explores the relationship of single nucleotide polymorphisms (SNPs) in genes related to imatinib pharmacokinetics and pharmacodynamics and PFS in imatinib-treated patients with advanced GIST. METHODS: In 227...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.